Search results for "Onset of action"

showing 10 items of 10 documents

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

2003

Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma. Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 µg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 µg/day (n…

AdultCyclopropanesMalePulmonary and Respiratory MedicineBudesonideAdolescentmedicine.drug_classAcetatesSulfidesFluticasone propionatechemistry.chemical_compoundDouble-Blind Methodimmune system diseasesAdministration InhalationHumansMedicineSingle-Blind MethodAnti-Asthmatic AgentsBudesonideMontelukastAgedAsthmaLeukotriene E4business.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeEditorialchemistryAnesthesiaQuinolinesCorticosteroidDrug Therapy CombinationFemaleOnset of actionSalmeterolbusinessmedicine.drugThorax
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

An overview of the clinical efficacy of mirtazapine

2002

Mirtazapine is at least as effective as the tricyclic antidepressants and trazodone in a wide range of patient subgroups including in- and out-patients with moderate to severe depression. It also appears to be at least as effective as the serotonin and noradrenaline reuptake inhibitor venlafaxine in the treatment of severely depressed melancholic patients. When compared with the selective serotonin reuptake inhibitors (SSRIs), mirtazapine shows a significantly earlier onset of action. Further analysis of a study comparing mirtazapine with the SSRI paroxetine indicated that early improvement was a highly sensitive predictor of later stable response for both drugs. The positive predictive val…

Time FactorsMirtazapineVenlafaxine HydrochlorideMirtazapineVenlafaxineMianserinAntidepressive Agents TricyclicPharmacologymedicineHumansPharmacology (medical)chemistry.chemical_classificationClinical Trials as TopicDepressive DisorderAdrenergic Uptake Inhibitorsbusiness.industryVenlafaxine HydrochlorideTrazodoneCyclohexanolsParoxetineAntidepressive AgentsParoxetinePsychiatry and Mental healthTreatment OutcomeNeurologychemistryNeurology (clinical)SerotoninOnset of actionbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTricyclicHuman Psychopharmacology: Clinical and Experimental
researchProduct

Neue orale Antikoagulanzien zur Therapie der venösen Thromboembolie

2011

In the current treatment of venous thromboembolism most patients are treated with vitamin K antagonists (VKA). VKA have many disadvantages including slow onset of action, multiple food and drug interactions and a large inter-individual variability in their efficacy. Recently several alternative oral anticoagulants have been developed, which have several advantages in comparison to VKA. So far two large randomized studies comparing new oral anticoagulants with VKA in patients with venous thromboembolism have been published: the RECOVER study with the oral direct thrombin antagonist dabigatran and the EINSTEIN-DVT study with the oral direct factor Xa-antagonist rivaroxaban. With regard to rec…

Rivaroxabanbusiness.industryGeneral MedicineVitamin kmedicine.diseaseDabigatranPulmonary embolismchemistry.chemical_compoundchemistryEdoxabanAnesthesiaMedicineApixabanOnset of actionbusinessVenous thromboembolismmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?

1997

The purpose of this article is to compare and contrast the benefits and limitations of antidepressant drugs. Several different classes of antidepressants are available for treatment of major depressive disorder, each with its own benefits and limitations as a result of its pharmacological profile. Tricyclic antidepressants (TCAs) and monoamine oxidase (MAO) inhibitors are effective in a large proportion of depressed patients, but their use is often limited by short- and long-term safety/tolerability problems. Selective serotonin reuptake inhibitors (SSRIs) exhibit comparable efficacy to TCAs in most patients, but may be less effective in certain patients. Additionally, SSRI use may by impac…

chemistry.chemical_classificationbusiness.industryVenlafaxinePharmacologymedicine.diseasePsychiatry and Mental healthNeurologychemistryTolerabilitymedicineAntidepressantMajor depressive disorderAnxietyPharmacology (medical)Neurology (clinical)Onset of actionmedicine.symptomReuptake inhibitorbusinessTricyclicmedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study

2004

BACKGROUND: Atopic dermatitis (AD) is a chronic allergic inflammatory disease, which manifests itself with eczematous skin lesions. OBJECTIVE: We compared the clinical efficacy of tacrolimus ointment (0.1%) given twice a day and oral cyclosporine (3 mg/kg) given once daily. Rescue medication for itching included cetirizine 10-20 mg (equal to one or two tables). METHODS: Thirty patients, aged 13-45 years (mean+/-SD 27.1+/-10.9), with a history of moderate-to-severe AD were randomized to treatments, 15 patients for each treatments. Assessment of efficacy was based on SCORAD, on scores of daily itching, erythema, interference with sleep, due to the skin condition and days without use of cetiri…

atopic dermatitiAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentErythemaImmunologyAdministration OralDermatitisSeverity of Illness IndexGastroenterologyDrug Administration ScheduleAtopicDermatitis AtopicOintmentsAtopyLeukocyte CountDouble-Blind MethodInternal medicinemedicineHumansImmunology and Allergy; oral cyclosporine; atopic dermatitis; randomized study [tacrolimus ointment]SCORADcetirizinetacrolimusmedicine.diagnostic_testatopic dermatitisbusiness.industryArea under the curveoral cyclosporineAtopic dermatitisImmunoglobulin EMiddle Agedmedicine.diseaseDermatologyTacrolimusCetirizineEosinophilstacrolimus ointment:CyclosporineFemaleOnset of actionmedicine.symptombusinessrandomized studyImmunosuppressive Agentsmedicine.drug
researchProduct

Bodyplethysmographischer Wirkeintritt von Formoterol bei Patienten mit mittel- bis schwergradiger partiell reversibler Atemwegsobstruktion

2002

BACKGROUND Formoterol is a long acting beta2-agonist used for the treatment of obstructive airway diseases. Compared with Salmeterol, Formoterol has a rapid onset of bronchodilation. There are only scant data regarding the comparative onset of action using bodyplethysmography in moderate to severely obstructive patients. METHODS In a mono-center, single-blinded parallel group study 60 patients (age: 61.9 +/- 12.8 years, 65 % male) with moderate to severe (mean FEV(1) 40.6 +/- 15.3 % of predicted), partially reversible (FEV(1) post bronchodilator > 15 % from baseline) airway obstruction were treated with either formoterol 12 microg bid or salmeterol 50 microg bid over a period of two weeks. …

Pulmonary and Respiratory Medicinebusiness.industryrespiratory systemAirway obstructionmedicine.diseaserespiratory tract diseasesAirway resistanceAnesthesiaBronchodilationmedicineFormoterolOnset of actionSalmeterolbusinessAirwayMorningmedicine.drugPneumologie
researchProduct

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

2012

Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain. The availability of supplemental doses of oral opioids, in addition to the continuous analgesic medication, is the main treatment suggested to manage pain flares.Oral transmucosal fentanyl citrate (OTFC) is the first product of a new generation of delivery systems, named rapid-onset opioids (ROOs), characterized by rapidity of effect and the short duration of analgesia. Controlled studies and long-term experience have shown that OTFC is an e…

PharmacologyClinical Trials as Topicbusiness.industryBreakthrough PainAnalgesicBreakthrough PainMouth MucosaCancerAdministration OralGeneral Medicinemedicine.diseaseFentaNYL CitratePain ladderAnalgesics OpioidFentanylAnesthesiaNeoplasmsmedicineEffective treatmentHumansPharmacology (medical)Onset of actionCancer painbusinessRandomized Controlled Trials as TopicExpert opinion on pharmacotherapy
researchProduct

Effectiveness and safety of dexamphetamine sulfate (Attentin

2021

Abstract Background: Randomized controlled trials have shown that dexamphetamine sulfate (DEX) is efficacious in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents; however, data on the effectiveness and safety of DEX in routine practice are scarce. Objective: This study investigated the long-term effectiveness and safety of Attentin® (immediate-release DEX) in children and adolescents with ADHD in routine practice. Methods: ATTENTION was a multicenter, prospective, observational, non-interventional study that enrolled pediatric patients with ADHD (aged 6-17 years) with a clinically inadequate response to previous methylphenidate (MPH) treatment. Pa…

Pediatricsmedicine.medical_specialtydexamphetamineRC435-571Impulsivitylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialchildrenlawRating scale030225 pediatricsmental disordersmedicineClinical endpointADHDPsychology0501 psychology and cognitive sciencesadolescentsPsychiatryMethylphenidatebusiness.industry05 social sciences3. Good healthBF1-990Blood pressureMedicineObservational studyOnset of actionmedicine.symptombusiness050104 developmental & child psychologymedicine.drugScandinavian journal of child and adolescent psychiatry and psychology
researchProduct

Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia

2018

Hyperkalemia is one of the most common electrolyte disturbances, especially among some groups of patients, such as in those with chronic kidney disease, diabetes or heart failure. Hyperkalemia has been associated with increased risks of mortality, arrhythmias, hospitalization and costs, as well as the need to down titrate/discontinue renin-angiotensin-aldosterone system inhibitors (RAASIs), despite their well-known cardiovascular and nephroprotective benefits. Current potassium binders have limitations (slow onset of action, limited selectivity for potassium binding, risk of drug interactions or gastrointestinal intolerance). Sodium zirconium cyclosilicate (SZC) is a new potassium binder re…

Hyperkalemiabusiness.industrySilicatesPotassiumchemistry.chemical_elementPharmacologymedicine.diseaseRenin-Angiotensin Systemchemistry.chemical_compoundchemistryTolerabilityHeart failureDiabetes mellitusPotassiumHumansHyperkalemiaPotassium binderMedicineOnset of actionmedicine.symptombusinessKidney diseaseDrugs of Today
researchProduct